Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
No endovascular innovation without evaluation in chronic cerebrospinal venous insufficiency: a call for the IDEAL model.
Williams MA, Venkatesan A.
Arch Neurol. 2011 Dec;68(12):1510-2. No abstract available.
Related citations
Myasthenia gravis-associated neuromyelitis optica-like disease: an immunological link between the central nervous system and muscle?
Vaknin-Dembinsky A, Abramsky O, Petrou P, Ben-Hur T, Gotkine M, Brill L, Brenner T, Argov Z, Karussis D.
Arch Neurol. 2011 Dec;68(12):1557-61. Epub 2011 Aug 8.
Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study.
Evans C, Tam J, Kingwell E, Oger J; University of British Columbia MS Clinic Neurologists, Tremlett H.
Clin Ther. 2012 Feb;34(2):341-50. Epub 2012 Jan 31.
Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.
Qizilbash N, Mendez I, Sanchez-de la Rosa R.
Clin Ther. 2012 Jan;34(1):159-176.e5. Review.
Exploring the role of the epigenome in multiple sclerosis: A window onto cell-specific transcriptional potential.
Kaliszewska A, De Jager PL.
J Neuroimmunol. 2012 Jan 30. [Epub ahead of print]
Data integration and systems biology approaches for biomarker discovery: Challenges and opportunities for multiple sclerosis.
Villoslada P, Baranzini S.
J Neuroimmunol. 2012 Jan 24. [Epub ahead of print]
Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica.
Zhong X, Wang H, Dai Y, Wu A, Bao J, Xu W, Cheng C, Lu Z, Qiu W, Hu X.
J Neuroimmunol. 2011 Dec 15;240-241:104-8. Epub 2011 Oct 28.
Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.
Laugel B, Borlat F, Galibert L, Vicari A, Weissert R, Chvatchko Y, Bruniquel D.
J Neuroimmunol. 2011 Dec 15;240-241:52-7. Epub 2011 Oct 26.
Th17 expansion in MS patients is counterbalanced by an expanded CD39+ regulatory T cell population during remission but not during relapse.
Peelen E, Damoiseaux J, Smolders J, Knippenberg S, Menheere P, Tervaert JW, Hupperts R, Thewissen M.
J Neuroimmunol. 2011 Dec 15;240-241:97-103. Epub 2011 Oct 26.
More to come: humoral immune responses in MS.
Dobson R, Meier UC, Giovannoni G.
J Neuroimmunol. 2011 Dec 15;240-241:13-21. Epub 2011 Oct 21. Review.
Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study.
Fernández O, Oreja-Guevara C, Arroyo R, Izquierdo G, Pérez JL, Montalban X.
J Neurol. 2012 Jan 31. [Epub ahead of print]
Using atypical symptoms and red flags to identify non-demyelinating disease.
Kelly SB, Chaila E, Kinsella K, Duggan M, Walsh C, Tubridy N, Hutchinson M.
J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):44-8. Epub 2011 Aug 17.
Evidence that the north-south gradient of multiple sclerosis may not have disappeared.
Grant WB, Mascitelli L.
J Neurol Sci. 2012 Apr 15;315(1-2):178-9. Epub 2012 Jan 30. No abstract available.
National estimate of multiple sclerosis incidence in France (2001-2007).
Fromont A, Binquet C, Sauleau E, Fournel I, Despalins R, Rollot F, Weill A, Clerc L, Bonithon-Kopp C, Moreau T.
Mult Scler. 2012 Feb 1. [Epub ahead of print]
Towards the incorporation of lumbar puncture into clinical trials for multiple sclerosis.
Gafson AR, Giovannoni G.
Mult Scler. 2012 Feb 1. [Epub ahead of print] No abstract available.
Color vision is strongly associated with retinal thinning in multiple sclerosis.
Villoslada P, Cuneo A, Gelfand J, Hauser SL, Green A.
Mult Scler. 2012 Jan 30. [Epub ahead of print]
Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis.
Simon KC, O'Reilly EJ, Munger KL, Finerty S, Morgan AJ, Ascherio A.
Factors associated with emotional and behavioral outcomes in adolescents with multiple sclerosis.
Till C, Udler E, Ghassemi R, Narayanan S, Arnold D, Banwell B.
Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
Gavasso S, Gjertsen B, Anderssen E, Myhr K, Vedeler C.
Mult Scler. 2012 Jan 27. [Epub ahead of print]
Risk stratification and patient counseling for natalizumab in multiple sclerosis.
Fox RJ, Rudick RA.
Neurology. 2012 Feb 7;78(6):436-7. Epub 2012 Jan 25. No abstract available.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on